JP2023522056A5 - - Google Patents

Info

Publication number
JP2023522056A5
JP2023522056A5 JP2022562978A JP2022562978A JP2023522056A5 JP 2023522056 A5 JP2023522056 A5 JP 2023522056A5 JP 2022562978 A JP2022562978 A JP 2022562978A JP 2022562978 A JP2022562978 A JP 2022562978A JP 2023522056 A5 JP2023522056 A5 JP 2023522056A5
Authority
JP
Japan
Prior art keywords
liraglutide
lenalidomide
azacitidine
active agent
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022562978A
Other languages
English (en)
Japanese (ja)
Other versions
JP7883442B2 (ja
JP2023522056A (ja
Filing date
Publication date
Priority claimed from GBGB2005593.5A external-priority patent/GB202005593D0/en
Application filed filed Critical
Publication of JP2023522056A publication Critical patent/JP2023522056A/ja
Publication of JP2023522056A5 publication Critical patent/JP2023522056A5/ja
Application granted granted Critical
Publication of JP7883442B2 publication Critical patent/JP7883442B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022562978A 2020-04-17 2021-04-16 新しい注射用油性医薬組成物 Active JP7883442B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2005593.5A GB202005593D0 (en) 2020-04-17 2020-04-17 New composition
GB2005593.5 2020-04-17
PCT/GB2021/050913 WO2021209762A1 (en) 2020-04-17 2021-04-16 Injectable oil-based pharmaceutical composition

Publications (3)

Publication Number Publication Date
JP2023522056A JP2023522056A (ja) 2023-05-26
JP2023522056A5 true JP2023522056A5 (cg-RX-API-DMAC10.html) 2024-04-19
JP7883442B2 JP7883442B2 (ja) 2026-07-01

Family

ID=70860026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562978A Active JP7883442B2 (ja) 2020-04-17 2021-04-16 新しい注射用油性医薬組成物

Country Status (9)

Country Link
US (1) US20230157968A1 (cg-RX-API-DMAC10.html)
EP (1) EP4135672A1 (cg-RX-API-DMAC10.html)
JP (1) JP7883442B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230004568A (cg-RX-API-DMAC10.html)
CN (1) CN116075295A (cg-RX-API-DMAC10.html)
AU (1) AU2021256075A1 (cg-RX-API-DMAC10.html)
CA (1) CA3179556A1 (cg-RX-API-DMAC10.html)
GB (1) GB202005593D0 (cg-RX-API-DMAC10.html)
WO (1) WO2021209762A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023105227A1 (en) * 2021-12-08 2023-06-15 Nanexa Ab New injectable combination formulation
GB2619556A (en) * 2022-06-10 2023-12-13 Nanexa Ab New process
AU2023392764A1 (en) * 2022-12-15 2025-06-19 Nanexa Ab New pharmaceutical compositions comprising glucagon-like peptide-1 receptor agonists
GB202218958D0 (en) 2022-12-15 2023-02-01 Nanexa Ab New pharmaceutical composition
CN117844877B (zh) * 2024-01-14 2024-09-06 宿州市东凯医药科技有限公司 一种通过生物酶制备普瑞巴林的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097742B2 (en) 2005-01-20 2012-01-17 Agency For Science, Technology And Research Water-soluble, surface-functionalized nanoparticle for bioconjugation via universal silane coupling
EP3685837A1 (en) * 2008-09-04 2020-07-29 Amylin Pharmaceuticals, LLC Sustained release formulations using non-aqueous carriers
KR102264011B1 (ko) 2013-05-24 2021-06-10 나넥사 에이비 무기성 코팅을 갖는 고형의 나노입자

Similar Documents

Publication Publication Date Title
JP2023115329A5 (cg-RX-API-DMAC10.html)
JP2020010717A5 (cg-RX-API-DMAC10.html)
JP2021509912A5 (cg-RX-API-DMAC10.html)
JP2022544380A5 (cg-RX-API-DMAC10.html)
JP2021129286A5 (cg-RX-API-DMAC10.html)
JP2025160243A5 (cg-RX-API-DMAC10.html)
MX2019012693A (es) Composiciones con polimeros anionicos y cationicos.
JP2021518134A5 (cg-RX-API-DMAC10.html)
JP2023113681A5 (cg-RX-API-DMAC10.html)
JP2017105763A5 (cg-RX-API-DMAC10.html)
JP2024037765A5 (cg-RX-API-DMAC10.html)
JP2024507827A5 (cg-RX-API-DMAC10.html)
JP2023041070A5 (cg-RX-API-DMAC10.html)
JP2002532112A5 (cg-RX-API-DMAC10.html)
JP2026004274A5 (cg-RX-API-DMAC10.html)
JPWO2022202973A5 (cg-RX-API-DMAC10.html)
JP2020109413A5 (cg-RX-API-DMAC10.html)
JP2023153863A5 (cg-RX-API-DMAC10.html)
JP2022538215A5 (cg-RX-API-DMAC10.html)
JP2025138639A5 (cg-RX-API-DMAC10.html)
CL2011003065A1 (es) Formulacion vesicular que comprende uno o mas fosfolipidos y uno o mas surfactantes no ionicos, libre de cualquier agente farmaceuticamente activo, util para el tratamiento del dolor asociado con osteoartritis.
JP2023502517A5 (cg-RX-API-DMAC10.html)
JP2023508938A5 (cg-RX-API-DMAC10.html)
JP2023139025A5 (cg-RX-API-DMAC10.html)
JP2023103231A5 (cg-RX-API-DMAC10.html)